Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Gastrointestinal Stromal Tumors 1Gastro-Intestinal Stromal Tumour 1Colorectal Neoplasms 1

Interventions

Irinotecan 58Bevacizumab 56Oxaliplatin 49Leucovorin 49Fluorouracil 49Capecitabine 45Cetuximab 44pembrolizumab 23IFL protocol 15Nivolumab 11regorafenib 10Panitumumab 10Celecoxib 8Radiotherapy 7Cyclophosphamide 7atezolizumab 6Surgical Procedures, Operative 6Gemcitabine 6Folfox protocol 6Colonoscopy 6trifluridine tipiracil drug combination 5Neoadjuvant Therapy 5Metformin 5Immunohistochemistry 5Biopsy 5tislelizumab 4spartalizumab 4durvalumab 4Trastuzumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colorectal Neoplasms × masitinib × Clear all
NCT02605044 2019-02-11

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

AB Science

Phase 3 Terminated
123 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡